Evidence map›Paper›PMID 32792855›Full record

ArticleInternational journal of biological sciences2020

Highly bioavailable Berberine formulation improves Glucocorticoid Receptor-mediated Insulin Resistance

Zhaojie Meng, Yang Yu, Yining Zhang, Xuehan Yang, Xiaoyan Lv, Fengying Guan, Grant M Hatch, Ming Zhang, Li Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Signaling pathways in obesity: mechanisms and therapeutic interventions.Signal transduction and targeted therapy · 2022
    Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Zhaojie MengDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Yang YuDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Yining ZhangThe First Hospital, Jilin University, Changchun, China.
Xuehan YangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Xiaoyan LvThe Second Hospital, Jilin University, Changchun, China.
Fengying GuanDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Grant M HatchDepartment of Pharmacology and Therapeutics, Center for Research and Treatment of Atherosclerosis, DREAM Manitoba Institute of Child Health, University of Manitoba, Winnipeg, Manitoba, Canada.
Ming ZhangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Li ChenDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin, China.
Jilin Medical University · CNJilin University · CNFirst Hospital of Jilin University · CNSecond Affiliated Hospital of Jilin University · CNUniversity of Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Excess glucocorticoid (GC) production is known to induce obesity and insulin resistance through increased activation of the glucocorticoid receptor (GR). The molecular mechanism for the non-genomic effects of excessive circulating GC on the insulin-signalling pathway in skeletal muscle is unknown. The plant alkaloid berberine has been shown to attenuate insulin resistance and inhibit gluconeogenesis in type 2 diabetic animals. A highly bioavailable berberine formulation termed Huang-Gui solid dispersion (HGSD), is a preparation of berberine coupled to sodium caprate and this markedly improving berberines bioavailability. Here we examined how HGSD treatment attenuated GR-mediated alteration in PI3K signalling and insulin resistance in diabetic rats, dexamethasone-treated mice and in insulin resistant C2C12 skeletal muscle cells. Blood glucose and skeletal muscle GC levels were increased and insulin signalling impaired in skeletal muscle of type 2 diabetic rats compared to controls. Treatment of these animals with HGSD restored blood glucose and skeletal muscle GC levels to that of controls. Insulin resistant C2C12 skeletal muscle cells exhibited impaired insulin signalling compared to controls and treatment of HGSD and RU486, an antagonist of GR, restored insulin signalling to that of control cells. Administration of dexamethasone to mice increased GR/GRα-associated PI3K and reduced IRS1-associated PI3K, phosphorylated-AKT, and membrane GLUT4 translocation resulting in a higher blood glucose concentration compared to controls. HGSD treatment of these mice improved insulin resistance by reducing the association of GR/GRα with PI3K. Excess GC-induced insulin resistance is mediated by increased association of GR with PI3K and treatment with HGSD attenuates these effects. We hypothesize that HGSD may be a promising candidate drug for the treatment of type 2 diabetes by reducing the association of GR with PI3K in skeletal muscle.

Indexed as

Insulin ResistanceAnimalsBerberineCell LineDexamethasoneDiabetes Mellitus, ExperimentalDrug Evaluation, PreclinicalInsulinMaleMiceMice, Inbred ICRMuscle, SkeletalPhosphatidylinositol 3-KinaseRandom AllocationRats, WistarReceptors, GlucocorticoidBerberineDexamethasoneInsulinPhosphatidylinositol 3-KinaseReceptors, Glucocorticoidglucocorticoid receptorHighly bioavailable berberine formulationHuang-Gui solid dispersioninsulin resistancephosphatidylinositol 3-kinase

Identifiers

PMID32792855
PMCPMC7415432
OpenAlexW3043824448

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.